Compound class:
Synthetic organic
Comment: Compound 27 was designed to offer improved clinical potential as a utrophin modulator than either ezutromid (failed at Phase 2) or SMT022357 (terminated at preclinical) [1]. This entry shows the compound without specified stereochemistry, to represent the racemic mixture. (+)-27 is slightly more active than (-)-27 or the racemate in vitro.
Clinical rationale: Up-regulation of utrophin (UTRN; P46939) as being investigated as a disease-modifying approach for Duchenne muscular dystrophy (DMD). In the mdx mouse DMD model, increased levels of utrophin effectively acts as a substitute for the dystrophin (DMD; P11532) that is missing in DMD [2]. |
|
References |
1. Babbs A, Berg A, Chatzopoulou M, Davies KE, Davies SG, Edwards B, Elsey DJ, Emer E, Guiraud S, Harriman S et al.. (2020)
2-Arylbenzo[d]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy. J Med Chem, 63 (14): 7880-7891. [PMID:32551645] |
2. Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE, Powell DS, Cozzoli A, Capogrosso RF, Lambert A et al.. (2011)
Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE, 6 (5): e19189. [PMID:21573153] |